Natera Inc (NASDAQ:NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company following a Hindenburg Research short report released the same morning criticizing Natera on "multiple fronts."
“Hindenburg's report questions NTRA's potential use of a third party (My Genome My Life, or MGML) for prior authorization facilitation, microdeletion testing, 'deceptive' billing practices and the regulatory/legal attention the company has received in recent years. Overall, we think many of the 'points' made by the author are not entirely new information,” the analyst wrote.
